TOPICAL PHARMACEUTICAL COMPOSITION BASED ON SEMIFLUORINATED ALKANES

• US 20140100180A1
• Filed: 05/24/2012
• Published: 04/10/2014
• Est. Priority Date: 05/25/2011
• Status: Active Grant

• Current Assignee: Dermaliq Therapeutics Incorporated
• Original Assignee: Novaliq GmbH
• Inventors: Theisinger, Bastian, Theisinger, Sonja, Gunther, Bernhard, Scherer, Dieter
• Granted Patent: US 10,130,707 B2
• Time in Patent Office: Days
• US Class Current: 514/29
• CPC Class Codes: A61K 31/355 Tocopherols, e.g. vitamin E
• CPC Class Codes: A61K 31/436 the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/06 Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/08 Solutions composition of solutions A61K47/00
• CPC Class Codes: A61K 9/1075 Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers A61K9/0026 takes precedence
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 17/10 Anti-acne agents
• CPC Class Codes: A61P 17/12 Keratolytics, e.g. wart or anti-corn preparations
• CPC Class Codes: A61P 17/14 for baldness or alopecia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14

Abstract

The invention provides liquid or semi-solid pharmaceutical compositions for topical administration comprising a semifluorinated alkane. The compositions are useful for the delivery of active ingredients into the deep layers of the skin or skin appendages. Various active ingredients may be incorporated, such as immunosuppressants, antiinfectives, antifungal agents, antiinflammatory agents, and retinoids.

Claims

1. A method for the prevention or treatment of a disease or condition affecting the skin or a skin appendage, comprising administering to the skin or skin appendage a topical pharmaceutical composition comprising an effective amount of an active ingredient and a semifluorinated alkane according to formula

RFRH

wherein RF is a linear perfluorinated hydrocarbon segment with 4 to 12 carbon atoms, and RH is a linear alkyl group with 4 to 8 carbon atoms.

3. The method of claim 1, wherein the composition is in the form of a liquid or semisolid solution, emulsion, or microemulsion.

4. The method of claim 1, wherein the composition comprises a physiologically acceptable cosolvent selected from ethanol, acetone, ethyl acetate, isopropyl alcohol, glycerol, propylene glycol, pentylene glycol, polyethylene glycol, liquid paraffin, triglyceride oils, hydrofluorocarbons such as HFA 134a and/or HFA 227, and liquid mono- or diglycerides.

5. The method of claim 1, wherein the skin or skin appendage is affected by a disease or condition selected from psoriasis, dermatitis, erythema, ekzema, allergy, acne, actinic keratosis, fungal infections, bacterial infections, viral infections, verrucae, or rosacea.

6. The method of claim 1, wherein the disease or condition affects the vital epidermis, dermis, and/or hypodermis of the skin.

7. The method of claim 1, wherein the skin is affected by psoriasis, and wherein the active ingredient is selected from immunosuppressants or retinoids.

8. The method of claim 7, wherein the immunosuppressant is selected from tacrolimus, sirolimus, everolimus, tacrolimus, pimecrolimus, ridaforolimus, temsirolimus, zotarolimus, and ciclosporin A.

9. The method of claim 7, wherein the retinoid is selected from retinol, retinal, tretinoin, isotretinoin, alitretinoin, etretinate, acitretin, tazarotene, bexarotene and adapalene.

10. The method of claim 1, wherein the skin is affected by acne, and wherein the active ingredient is selected from retinoids or antiinfective agents.

11. The method of claim 10, wherein the retinoid is selected from retinol, retinal, tretinoin, isotretinoin, alitretinoin, etretinate, acitretin, tazarotene, bexarotene and adapalene.

12. The method of claim 10, wherein the antiinfective agents is selected from azithromycin, erythromycin, clindamycin, or minocycline.

13. The method of claim 1, wherein the skin is affected by actinic keratosis, and wherein the active ingredient is selected from diclofenac, 5-fluorouracil and imiquimod.

2. The method of claim 2, wherein the semifluorinated alkane is selected from F4H5, F4H6, F4H8, F6H6 and F6H8, wherein F means a perfluorinated hydrocarbon segment, H means a non-fluorinated segment, and the number is the number of carbon atoms of the respective segment.

14. (canceled)

15. A method for delivering an active ingredient to the vital epidermis, dermis, and/or hypodermis of the skin comprising topically administering to the skin or skin appendage a topical pharmaceutical composition comprising an effective amount of the active ingredient and a semifluorinated alkane according to formula

RFRH

wherein RF is a linear perfluorinated hydrocarbon segment with 4 to 12 carbon atoms, and RH is a linear alkyl group with 4 to 8 carbon atoms.